Zydus unit acquires global rights to Eiger BioPharma’s Zokinvy

4 May 2024

Sentynl Therapeutics, the USA-based wholly-owned subsidiary of Indian generics major Zydus Lifesciences (NYSE: ZYDUSLIFE), has announced the closing of the sale of Eiger BioPharmaceuticals’ (OTC: EIFRQ) Zokinvy (lonafarnib) program to Sentynl.

Shares of insolvent rare disease drug developer Eiger closed up more than 12% at $2.69 following the announcement on Friday.

As previously disclosed by Eiger, on April 1, 2024, Eiger and its direct subsidiaries filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code (Chapter 11 Cases) in the US Bankruptcy Court for the Northern District of Texas (Bankruptcy Court).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK